

## DAFTAR PUSTAKA

- Advani, R.H., Chen, H., Habermann, T.M., Morrison, V.A., Weller, E.A., *et al*; Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; Southwest Oncology Group. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). *Br J Haematol* 2010; 151: 143-151.
- Akobeng, A. K., 2007. Understanding diagnostic tests 3: receiver operating characteristic curves. *Acta Paediatrica*. 96; 644-647.
- Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, *et al*. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* [Internet]. 2000;403(6769):503–11. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10676951>
- Altman, Edward, I. 2000, Predicting Financial Distress of Companies : Revisiting The Z-score and Zeta ® Models, New York University, Stern School of Business
- Andreone, P., Gramenzi, A., Lorenzini, S., Biselli, M., Cursaro C, Pileri S, *et al*. Posttransplantation lymphoproliferative disorders. *Arch Intern Med* [Internet]. 2003;163(17):1997–2004. Available from: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=14504111](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14504111)
- Ansell, S.M., Stenson, M., Habermann, T.M., Jelinek, D.F., Witzig, T.E. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. *Ansell J Clin Oncol* 2001;19:720–6.
- Aoki, K., Tabata, S., Yonetani, N., Matsushita, A., Ishikawa, T. The prognostic impact of absolute lymphocyte and monocyte counts at diagnosis of diffuse large B-cell lymphoma in the rituximab era. *Acta Haematol* 2013;130:242–6 [Epub ahead of print].
- Atzpodien, J., Reitz, M. 2008. Peripheral blood neutrophils as independent immunologic predictor of response and longterm survival upon immunotherapy in metastatic renal-cell carcinoma. *Cancer Biotherapy and Radiopharmaceuticals*, 23: 1, pp. 129–134.
- Bakhshi, A., Jensen, J.P., Goldman, P., Wright, J.J., McBride, O.W., Epstein, A.L., *et al*. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18. *Cell*. 1985;41(3):899–906.
- Balkwill, F., Mantovani, A. 2010. Cancer and inflammation: implications for pharmacology and therapeutics. *Clin Pharmacol Ther*, 87: 401-406.
- Bambace, N.M., Holmes, E.C. 2011. The platelet contribution to cancer progression. *J Thromb Haemost*, 9: 237–49.

Batty, N., Ghonimi, E., Feng, L., Fayad, L., Younes, A., Rodriguez, M.A., *et al.* The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. *Clin Lymphoma Myeloma Leuk* 2013;13:15–8.

Belloq, A., Antoine, M., Flahault, A., *et al.* 1998. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. *The American Journal of Pathology*, 152: 1, pp. 83–92.

Belotti, A., Doni, E., Bolis, S., Rossini, F., Casaroli, I., Pezzatti, S., *et al.* Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era. *Clin Lymphoma Myeloma Leuk* 2015; 15: 208-13.

Bergsagel, P.L., Chesi, M., Nardini, E., Brents, L.A., Kirby, S.L., Kuehl, WM. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. *Proc Natl Acad Sci* [Internet]. 1996;93(24):13931–6. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.93.24.13931>

Bernstein, L., Ross, R.K. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. *Cancer Res.* 1992;52(19 Suppl):5510s–5515s.

Bhumsuk, K., Hyerim, H., Tae Min Kim, Yoon Kyung, J., *et al.* The neutrophil to lymphocyte ratio improves the prognostic prediction of the International Prognostic Index for diffuse large B-cell lymphoma patients treated with R-CHOP. 2014. DOI: 10.3109/10428194.2014.982642.

Boulanger, E., Duprez, R., Delabesse, E., Gabarre, J., Macintyre, E., Gessain A. Mono/oligoclonal pattern of Kaposi Sarcoma-associated herpesvirus (KSHV/HHV-8) episomes in primary effusion lymphoma cells. *Int J Cancer.* 2005;115(4):511–8.

Brian, R., David, G., DeNardo, Nesrine, I., Affara, and Lisa M. Coussens. Lymphocytes in cancer development: polarization towards protumor immunity. *NIH Public Access*, 2010.

Burnet, F.M. 1970. The concept of immunological surveillance. *Prog Exp Tumor Res*, 13:1–27.

Campo, E., Swerdlow, S.H., Harris, N.L., Pileri, S., Stein, H., Jaffe, E.S. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. *Blood.* 2011;117(19):5019–32.

Caputto, L.Z., Luiz, A., Fonseca, A., Pereira, J., Luiz, F., *et al.* Exames laboratoriais complementares indicados no apoio ao diagnóstico do linfoma difuso de grandes células B (LDGCB). *Arq Bras Ciências da Saúde.* 2008;33(3):185–94.

Cencini, E., Fabbri, A., Sicuranza, A., Bocchia, M. Prognostic Significance of lymphocyte Monocyte count and neutrophil lymphocyte count in peripheral T cell Lymphoma. *Leuk Res.* 2019; 77:5-7

Chen, Y., Neclapsu, S., Feng, L., Bi W, Yang TH, Wang M, *et al.* prognostic Significance of baseline Peripheral Absolute Neutrophyl, monocyte, and serum Beta 2 microglobulin level in Patients with Diffuse Large B cell Lymphoma: A new Prognostic Model. *Br J Haematol.* 2016; 175(2): 290-9

Ching-Liang Ho., Chieh-Sheng, L., Jia-Hong, C., *et al.* Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma. *Medicine* Volume 94, Number 24, June 2015

Clarke, C.A., Glaser, S.L. Changing incidence of non-Hodgkin lymphomas in the United States. *Cancer*. 2002;94(7):2015–23.

Coiffier, B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. *J Clin Oncol* 2005;23:6387–93.

Consensus document for management of Non Hodgkin's Lymphoma (High Grade), Indian Council of Medical Research, New Delhi, 2016

Cox, M.C., Nofroni, I., Ruco, L., Amodeo, R., Ferrari, A., La Verde, G., *et al.* Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. *Leuk Lymphoma* 2008;49:1745–51.

Cultrera, J.L., Dalia, S.M. Diffuse large B-cell lymphoma: current strategies and future directions. *Cancer Control* 2012; 19: 204-13.

Dahlan, Sopiudin M. Statistik untuk Kedokteran dan Kesehatan Edisi Kelima. Jakarta: Salemba Medika. 2012

Davalyn, R.. Powell and Anna Huttenlocher. Neutrophils in the Tumor Microenvironment. <http://dx.doi.org/10.1016/j.it.2015.11.008>.

De Jong, D, Enblad, G. inflammatory Cells and Immune Microenvironment in Malignant Lymphoma. *JIntern Med*. 2008; 264(6): 528-536

De Re V., De Vita, S., Marzotto. A, Rupolo M, Gloghini, A., Pivetta, B., *et al.* Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. *Blood* [Internet]. 2000;96(10):3578–84. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11071657>

Della Bella, S., Bierti, L., Presicce, P., Arienti, R., Valenti, M., Saresella, M., *et al.* Peripheral blood dendritic cells and monocytes are differently regulated in the elderly. *Clin Immunol*. 2007; 122(2); 220-8.

Dirkx, A.E., Oude Egbrink, M.G., Wagstaff J, Griffioen AW. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. *J Leukoc Biol* 2006;80:1183–96 [Epub 2006 Sep 22. Review]

Dolcetti, R., Martini, F., Quaia, M., Gloghini, A., Vignocchi, B., Cariati, R., *et al.* Simian Virus 40 Sequences in Human Lymphoblastoid B-Cell Lines. *Society*. 2003;77(2):1595–7.

Earl R Babbie. Survey research methods. Belmont, Calif., Wadsworth Pub. Co. [1973]

Ehrlich, P. 1909. The current state of cancer research (Über den jetzigen stand der karzinomforschung). *Ned Tijdschr Geneesk*, 5:273–290.

Ekström-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma - A review. *Acta Oncol (Madr)*. 2006;45(3):258–71.

Eri Matsuki, Olga L. Bohn, Siraj El Jamal, *et al.* Lymphocyte-To-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-Associated- Macrophages in DLBCL Treated with Rituximab. *Appl Immunohistochem Mol Morphol*. 2019 September ; 27(8): 572–580

Ery Kus, D., Indrawati, Hardianti, M. S., Ghazali, R., *et al.* Histopathological Features of Lymphoma in Yogyakarta, Indonesia. *Asian Pac J Cancer Prev*, 2016;17 (9), 4213 – 4216.

Feng, J., Wang, Z., Guo, X., Chen, Y., Cheng, Y., Tang, Y. Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis. *Int J Hematol* 2012;95:143–8.

Ferlay, J., Soerjomataram, I.I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., *et al.* Cancer incidence and mortality worldwide : sources , methods and major patterns in GLOBOCAN 2012. 2012;

Filipovich, H., Mathur, A., Kamat, D., Shapiro, R.S. Primary Immunodeficiencies : Genetic Risk Factors for Lymphoma Primary Immunodeficiencies : Genetic Risk Factors for Lymphoma1. 1992;(6):5465–7.

Fugmann, S.D., Lee, A.I., Shockett, P.E., *et al*: The RAG proteins and V(D)J recombination: Complexes, ends, and transposition. *Annu Rev Immunol* 18:495- 527, 2000.

Gabrilovich, D.I., Nagaraj, S. 2009. Myeloid-derived suppressor cells as regulators of the immune system. *Nature Reviews Immunology*, 9; 3, pp. 162–174.

Gabrilovich, D.I., Ostrand-Rosenberg, S., Bronte, V. 2012. Coordinated regulation of myeloid cells by tumours. *Nat Rev Immunol*, 12(4): 253–268.

Gisbert ,J.P., García-Buey, L., Pajares, M.J., Moreno-Otero, R. Prevalence of Hepatitis C Virus Infection in B-Cell Non-Hodgkin's Lymphoma: Systematic, Review and Meta-Analysis. *Gastroenterology*. 2003;125(6):1723–32.

Gisbert, J.P., Garcia-Buey, L., Pajares, J.M., Moreno-Otero, R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. *Aliment Pharmacol Ther* [Internet]. 2005;21(6):653–62. Available from: <http://doi.wiley.com/10.1111/j.1365-2036.2005.02395.x>.

Grivennikov, S.I., Greten, F.R., Karin, M. 2010. Immunity, inflammation, and cancer. *Cell*, 140(6): 883–899.

Gustaf, H., Oskar, H., Mats, J., Gunilla. E & on behalf of the Swedish Lymphoma Study Group. 2015. The impact of age on survival of diffuse large B-cell lymphoma – a population-based study. *Acta Oncologica*, 2015; 54: 916–923

Hagerling, C., Casbon, A.J., Werb, Z. Balancing the Innate Immune system in Tumor Development. *Trends Cell Biol*. 2015; 25(4): 214-20

Hamlin, P.A., Zelenetz, A.D., Kewalramani, T., Qin, J., Satagopan, J.M., Verbel, D., *et al.* Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. 2003;102(6):1989–96.

Heather, J., Dalton, Guillermo, N., Armaiz-Pena, Vianey Gonzalez-Villasana, *et al.* Monocyte Subpopulations in Angiogenesis. *Cancer Res* 2014;74:1287-1293

Hendrik Nogai, Bernd Dörken, and Georg Lenz. Pathogenesis of Non-Hodgkin's Lymphoma. *Jurnal of clinical oncology*. 2011

<https://canreg.fk.ugm.ac.id/laporan-data/rkbr-maret-2018/>

Holly, E.A., Lele, C., Bracci, P.M., McGrath, M.S. Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. *Am J Epidemiol* [Internet]. 1999;150(4):375–89. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10453814>

Hui-ling, S., Yu-Qin, P., Bang-shun he., Zhen-lin nie, *et al.* Prognostic performance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: an updated meta-analysis of eleven reports. 2016. *OncoTargets and Therapy* 2016:9.

Hung, M.H., Yu, Y.B., Huang, Y.C., Liu, H.T., Hong, Y.C, Hsiao, L.T, *et al.* Patients with Diffuse Large B Cell Lymphoma in Partial response or stable disease after first line R-CHIP: prognostic Value of the Absolute Lymphocyte count and impact of autologous stem Cell transplantation. *Ann Hematol*. 2012; 91(12): 1907-15

Hussell, T., Isaacson, P.G., Crabtree, J.E., Spencer, J.O. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. *J Pathol*. 1996;178(2):122–7.

Isaacson, P.G. Update on MALT lymphomas. *Best Pract Res Clin Haematol*. 2005;18(1 SPEC. ISS.):57–68.

Jeang, K.T., Giam, C.Z., Majone, F., Aboud, M. Life, death, and tax: Role of HTLV-I oncoprotein in genetic instability and cellular transformation. *J Biol Chem*. 2004;279(31):31991–4.

Jaffe, E.S. Pathology & genetics: tumours of haematopoietic and lymphoid tissues. *WHO classification of tumours, pathology and genetics series 3*. IARC Press; 2001.

Jeune, C.L., Bertoli, S., Elhamri, M., Vergey, F., Borel, C., Huguet, F., *et al.* Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. *Leuk Lymphoma* 2013.

Jin Wang, Xu, Z., Yu, L., Zheng, L., Xiang, L. Prognostic significance of neutrophil-to lymphocyte ratio in diffuse large B-cell lymphoma: A meta-analysis. 2017. *PLOS ONE* <https://doi.org/10.1371/journal.pone.0176008>

Kate R Shankland, James, O.A., Barry, W.H. Non Hodgkin Lymphoma. *Lancet* 2012; 380: 848–57



Kim, D.H., Baek, J.H., Chae, Y.S., Kim, Y.K., Kim, H.J., Park, Y.H., et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. *Leukemia* 2007;21:2227–30.

Koduru, S., Wong, E., Strowig, T., et al. 2012. Dendritic cell-mediated activation induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma. *Blood*, 119(10):2302–2309

Koh, Y.W., Kang, H.J., Park, C., Yoon, D.H., Kim, S., Suh, C., et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages. *Oncologist* 2012;17:871–80.

Leandro, M.J., Isenberg, D.A. Rheumatic diseases and malignancy--is there an association?. *Scand J Rheumatol* [Internet]. 2001;30(4):185–8. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11578009>.

Lechner, M.G., Liebertz, D.J., Epstein, A.L. 2010. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. *The Journal of Immunology*, 185: 4: pp. 2273–2284.

Lenz, G., Nagel, I., Siebert, R., Anna, V., Sanger, W., Wright, G.W., et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell – like diffuse large B cell lymphoma. 2007;204(3):633–43.

Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., et al. Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signature in large B cell lymphomas. *N Engl J Med* 2008;22:2313–23.

Lenz, G., Wright, G.W., Emre, N.C.T., Kohlhammer, H., Dave, S.S., Davis, R.E., et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. *Pnas*. 2008;105(36):13520–5.

Li, Y.L., Gu, K.S., Pan, Y.Y., Jiao, Y., Zhai, Z.M. Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. *BMC Cancer* 2014; 14: 341.

Li, Z.M., Huang, J.J., Xia, Y., Sun, J., Huang, Y., Wang Y., et al. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. *PLoS One* 2012;7:e41658

Liu, M., Duke, J.L., Richter, D.J., Vinuesa, C.G., Goodnow, C.C., Kleinstein, S.H., et al. Two levels of protection for the B cell genome during somatic hypermutation. *Nature*. 2008;451(7180):841–5.

Manfroi, B., Moreaux, J., Righini, C., Ghiringhelli, F., Sturm, N., Huard, B. Tumor Associated Neutrophils Correlated with poor prognostic in Diffuse Large B Cell Lymphoma Patients. *Blood Cancer J*. 2018;8(7):66

Mantovani, A., Allavena, P., Sica, A., Balkwill, F. 2008. Cancer related inflammation. *Nature*, 454: 436-444.

Marie de Charette and Roch Houot. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. *Haematologica* 2018 Volume 103(8):1256-1268.

McKean-Cowdin, Feigelson H, Ross R, Pike M, Henderson B. Declining cancer rates in the 1990s. *J Clin Oncol*. 2002;18(11):2258–68.

Migliazza, A., Martinotti, S., Chen, W., Fusco, C., Ye, B.H., Knowles, D.M., *et al*. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. *Proc Natl Acad Sci U S A*. 1995;92(26):12520–4.

Mitri, J., Castillo, J., Pittas, A.G. Diabetes and risk of non-hodgkin's lymphoma: A meta-analysis of observational studies. *Diabetes Care*. 2008;31(12):2391–7.

Montesinos-Rongen, M., Besleaga, R., Heinsohn, S., Siebert, R., Kabisch, H., Wiestler, O.D., *et al*. Absence of simian virus 40 DNA sequences in primary central nervous system lymphoma in HIV-negative patients. *Virchows Arch* [Internet]. 2004;444(5):436–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15042369>

Morin, R.D., Johnson, N.A., Severson, T.M., Mungall, A.J., An, J., Goya, R., *et al*. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. *Nat Genet* [Internet]. 2010;42(2):181–5. Available from: <http://dx.doi.org/10.1038/ng.518>

Morton, L.M., Wang, S.S., Devesa, S.S., Hartge, P., Weisenburger, D.D., Linet, M.S. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. *Blood*. 2006;107(1):265–76.

Morton, L.M., Turner, J.J., Cerhan, J.R., Linet, M.S., Treseler, P.A., Clarke, C. A., *et al*. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110(2):695–708.

Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y., Honjo, T. Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase ( AID ), a Potential RNA Editing Enzyme. 2000;102:553–63.

Müller, A.M.S., Ihorst, G., Mertelsmann, R., Engelhardt, M. Epidemiology of non-Hodgkin ' s lymphoma ( NHL ): trends , geographic distribution , and etiology. 2005;1–12.

Nagaraj, S., Schrum, A.G., Cho, H.I., Celis, E., Gabrilovich, D.I. 2010. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. *The Journal of Immunology*, 184: 6, pp. 3106–3116.

Nam, S.J., Go, H., Paik, J.H., Kim, T.H., Heo, D.S, Kim, C.W, *et al*. An increase of M2 macrophages predict poor prognosis in patients with diffuse large B cell lymphoma treated with rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone. *Leuk Lymphoma*. 2014;55(11):2466-76

Nardini, E., Aiello, A., Giardini, R., Colnaghi, M.I., Menard, S., Balsari, A. Detection of aberrant isotype switch recombination in low-grade and high-grade gastric MALT lymphomas. *Blood* [Internet]. 2000;95(3):1032–8. Available from: <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L30062728%5>

[Cnhttp://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=00064971&id=doi:&atitle=Detection+of+aberrant+isotype+switch+recombination+in+low-grade+and+high-grade+gastric+MALT+lymp](http://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=00064971&id=doi:&atitle=Detection+of+aberrant+isotype+switch+recombination+in+low-grade+and+high-grade+gastric+MALT+lymp)

Negri, E., Little, D., Boiocchi, M., La Vecchia, C., Franceschi, S. B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: A systematic review. *Int J Cancer*. 2004;111(1):1–8.

Nicolas Batty, Elham, G. , Lei Feng, Luis, F., Anas, Y., Maria Alma., Jorge, R., *et al.* The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP. *Elsevier* 2013.

Novak, A.J., Grote, D.M., Stenson, M., Ziesmer, S.C., Witzig, T.E., Habermann, T.M., *et al.* Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. *Blood* 2004;104:2247–53.

Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., *et al.* Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. *Am J Clin Oncol* 5:649-655, 1982

Markovic, O., Popovic, L., Marisavljevic, D., *et al.* Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. *European Journal of Internal Medicine* 25 (2014) 296–302

Opelz, G., Döhler, B. Lymphomas after Solid Organ Transplantation: A Collaborative Transplant Study Report. *Am J Transplant*. 2004;4(2):222–30.

Pasqualucci, L., Guglielmino, R., Houldsworth, J., Mohr, J., Aoufouchi, S., Polakiewicz, R., *et al.* Expression of the AID protein in normal and neoplastic B cells. *Cell* 2016;104(10):3318–26.

Peranzoni, E., Zilio, S., Marigo, I., *et al.* 2010. Myeloid-derived suppressor cell heterogeneity and subset definition. *Current Opinion in Immunology*, 22: . 2, pp. 238–244.

Plonquet, A., Haioun, C., Jais, JP., Debard, AL., Salles, G., Bene, MC., *et al.* Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2–3 diffuse large B-cell lymphoma. *Ann Oncol* 2007;18:1209–15.

Porrata, LF., Gertz, MA., Inwards, DJ., Litzow, MR., Lacy, MQ., Tefferi, A., *et al.* Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. *Blood* 2001;98: 579–85.

Porrata, LF., Ristow, K., Colgan, JP., Habermann, TM., Witzig, TE., Inwards DJ, *et al.* Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. *Haematologica* 2012;97:262–9

Porrata, LF., Ristow, K., Colgan, JP., Habermann, TM., Witzig, TE., Inwards, DJ., *et al.* Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. *Haematologica* 2012;97:262–9.

Porrata, LF., Ristow, K., Habermann, TM., Witzig, TE., Colgan, JP., Inwards, DJ., Ansell, SM., Micallef, IN. *et al.* Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. *Leuk Lymphoma* 2014; 55: 2728-38.



Porrata, L.F., Ristow, K., Habermann, T.M., Witzig, T.E., Colgan, J.P., Inwards, D.J., Ansell, S.M., Micallef, I.N., Johnston PB., *et al.* Peripheral blood lymphocyte/ monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. *Br J Haematol* 2012; 157: 321-30.

Porrata, L.F., Ristow, K., Inward, D.J., Ansell, S.M., Micallef, I.N., Johnston, P.B. *et al.* Lymphopenia assessed during routine follow up after immunochemotherapy (R-CHOP) is a risk factor predicting relapse in patients with diffuse large b cell lymphoma. *Leukemia*. 2010; 24(7):1343-9

Raghavan, S.C., Swanson, P.C., Wu, X., Hsieh, C.L., Lieber, M.R. A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex. *Nature*. 2004;428(6978):88–93.

Rajewsky, K: Clonal selection and learning in the antibody system. *Nature* 381:751-758, 1996

Rambaldi, A., Boschini, C., Gritti, G., Delaini, F., Oldani, E., Rossi, A., *et al.* The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. *Am J Hematol* 2013;88(12):1062–7.

Ramiro, A.R., Jankovic, M., Eisenreich, T., Difilippantonio, S., Chen-Kiang, S., Muramatsu, M., *et al.* AID is required for c-myc/IgH chromosome translocations in vivo. *Cell*. 2004;118(4):431–8.

Ray-Coquard, I., Cropet, C., Van Glabbeke M., *et al.* Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas and lymphomas. *Cancer Res* 2009;69:5358–91.

Reksodiputro, A.H. Multicentre Epidemiology and Survival Study of B Cell Non Hodgkin Lymphoma Patients In Indonesia. *J Blood Disord Transfus* [Internet]. 2015;6(2):2–6.

Riihijarvi S, Fiskvik I, Taskinen M, *et al.* Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. *Haematologica*. 2015; 100:238–45. [PubMed: 25381134]

Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., *et al.* The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. *N Engl J Med* [Internet]. 2002;346(25):1937–47. Available from: <http://www.nejm.org/doi/abs/10.1056/NEJMoa012914>

Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaular, P., Gascoyne, R.D., *et al.* Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. *J Exp Med* [Internet]. 2003;198(6):851–62. Available from: <http://www.jem.org/lookup/doi/10.1084/jem.20031074>.

Prinja, S., Nidhi, G., Ramesh, V. Censoring in clinical trials: Review of survival analysis techniques. London School of Hygiene and Tropical Medicine, Keppel Street, London, UK, 2010.

Savage, K.J., Monti, S., Kutok, J.L., Cattoretti, G., Neuberg, D., Leval, L., *et al.* The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. *Blood*. 2014;102(12):3871–80.

Sastroasmoro, S., Ismail, S. 2014. In Dasar-dasar Metodologi Penelitian Klinis. 5<sup>th</sup> ed. Jakarta: CV. Sagung Seto, pp. 368 - 76.

Schumacher, T.N., Schreiber, R.D. 2015. Neoantigens in cancer immunotherapy. *Science*, 348(6230): 69–74.

Schmidt, H., Bastholt, L., Geertsens, P., Christensen, I.J., Larsen, S., Gehl, J., *et al.* Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. *Br J Cancer* 2005;93:273–8.

Sehn, L.H., Berry, B., Chhanabhai, M., Fitzgerald, C., *et al.* The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. *Blood* 2007; 109: 1857-61.

Seiffert, M., Schulz, A., Ohl, S., *et al.* Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. *Blood* 2010; 116: 4223-30.

Shalapour, S., Karin, M. 2015. Immunity, inflammation, and cancer: an eternal fight between good and evil. *J Clin Invest*, 125(9): 3347–3355.

Shankland, K.R., Armitage, J.O., Hancock, B.W. Non-Hodgkin lymphoma. *Lancet* [Internet]. 2012;380(9844):848–57. Available from: [http://dx.doi.org/10.1016/S0140-6736\(12\)60605-9](http://dx.doi.org/10.1016/S0140-6736(12)60605-9)

Shia, K.H. High frequency of germinal centre derivation in diffuse large B cell lymphoma from Asian patients. *J Clin Pathol* [Internet]. 2005;58(9):962–7. Available from: <http://jcp.bmj.com/cgi/doi/10.1136/jcp.2004.022624>

Shih-Feng, C., Yi-Chang, L., Hui-Hua, H., *et al.* 2017. Investigation on treatment strategy, prognostic factors, and risk factors for early death in elderly Taiwanese patients with diffuse large B-cell lymphoma. [www.nature.com/scientificreports](http://www.nature.com/scientificreports)

Shivakumar, L., Ansell, S. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies. *Clin Lymphoma Myeloma* 2006;7:106–8.

Shipp, M.A., Ross, K.N., Tamayo, P., Weng, A.P., Kutok, J.L., Aguiar, R.C., *et al.* Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. *Nat Med* ; 2002;8:68–74.

Shurin, M.R. 2012. Cancer as an immune-mediated disease. *ImmunoTargets and Therapy*, 1: 1–6.

Siddiqui, M., Ristow, K., Markovic, S.N., Witzig, T.E., Habermann, T.M., Colgan, J.P., *et al.* Absolute lymphocyte count predicts overall survival in follicular lymphomas. *Br J Haematol* 2006;134:596–601.

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., *et al.* 2014. Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N Engl J Med*, 371: 2189-99.

Song, M.K., Chung, J.S., Seol, Y.M., Kim, S.G., Shin, H.J., Choi, Y.J., *et al.* Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. *Ann Oncol* 2010;21:140–4.

Su, G.H. Defective B cell receptor-mediated responses in mice lacking the Ets protein, Spi-B. *EMBO J* [Internet]. 1997;16(23):7118–29. Available from: <http://emboj.embopress.org/cgi/doi/10.1093/emboj/16.23.7118>.

Steven, H., Swerdlow, Elias, C., Stefano, A., Piler, *et al.* The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood First Edition paper*, March 15, 2016; DOI 10.1182/blood-2016-01-643569

Swerdlow SH, Campo E, Harris NL, *et al.* WHO classification of tumours of haematopoietic and lymphoid tissues. ed 4th. Lyon, France: IARC Press; 2008.

The international Non-Hodgkin's Lymphoma prognostic Factors project. A predictive model for aggressive non- Hodgkin's lymphoma. *N Engl J med* 1993;329:987-94

Thoraya, A., Mohamed, S., Hanan, R., Marowa, M., Nadia, M. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study. *Journal of the Egyptian National Cancer Institute* (2011) 23, 17–24

Tran, H., Nourse, J., Hall, S., Green, M., Griffiths, L., Gandhi, M.K. Immunodeficiency associated lymphomas. *Blood Rev* 2008;22:261–81

Turner, C.A., Mack, D.H., Davis, M.M. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. *Cell*. 1994;77(2):297–306.

Uribe-Querol, E., Rosales, C. 2015. Neutrophils in cancer: two sides of the same coin. *Hindawi*, 2015.

Vaidya R & T. E. Witzig. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. *Annals of Oncology* 25: 2124–2133, 2014.

Vanneman, M., Dranoff, G. 2012. Combining immunotherapy and targeted therapies in cancer treatment. *Nat Rev Cancer*, 12(4): 237–251.

Wang, J., Gao, K., Lei, W., Dong, L., Xuan, Q., *et al.* lymphocyte to monocyte ratio is associated with prognostic of Diffuse Large B cell Lymphoma: correlation with CD 163 positive m2 type tumor-associated macrophages, not pd-1 positive tumor-infiltrating lymphocytes. *Oncotarget*. 2017;8(3):5414-25

Wang, J., Zhou, M., Xu, J.Y., Chen, B., Ouyang, J. Combination of Bcl-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma. *Onco Targets*. 2015; 8: 2645-2650.

Wang, J., Zhou, M., Xu, J.Y., Yang, Y.G., Zhang, Q.G., Zhou, R.F., Chen, B., Ouyang, J., Li, C. MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. *Histol Histopathol* 2016; 31: 285-92.

Wang, S., Ma, Y., Sun, L., Shi, Y., Jiang, S., Yu, K., *et al.* Prognostic Significance of pretreatment Neutrophil lymphocyte ratio and platelet lymphocyte ratio in patients with Diffuse Large B Cell Lymphoma. *Biomed Res Int.* 2018; 2018: 9651254

Wang, X., Li, Z., Naganuma, A., Ye, B.H.. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. *Proc Natl Acad Sci [Internet]*. 2002;99(23):15018–23. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.232581199>.

Wallach, D., Kang, T.B., Kovalenko, A. 2014. Concepts of tissue injury and cell death in inflammation: a historical perspective. *Nat Rev Immunol*, 14(1): 51–59.

Watanabe, R., Tomita, N., Itabashi, M., Ishibashi, D., Yamamoto, E., Koyama, S., Miyashita K, Takahashi H, Nakajima Y, Hattori Y, *et al.* . Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. *Eur J Haematol* 2014; 92: 204-10

Wen-Kai Xia, Qing-Fen, L., Dong, S., Zhi-Li, L., Jun, S., Wei-Dong, M. Prognostic significance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis. 2016. doi:10.1002/2211-5463.12066.

Wilcox, R.A., Ristow, K., Habermann, T.M., *et al.* The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large B-cell lymphoma. *Leukemia* 2011;25:1502–9

Wilcox, R.A., Wada, D.A., Ziesmer, S.C., *et al.* Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. *Blood* 2009; 114:2936-44.

Willett, E.V., Morton, L.M., Hartge, P., Becker, N., Bernstein, L., Boffetta, P., *et al.* Non-Hodgkin lymphoma and obesity: A pooled analysis from the InterLymph consortium. *Int J Cancer.* 2008;122(9):2062–70.

Wotherspoon, A.C., Ortiz-Hidalgo, C., Falzon, M.R., Isaacson, P.G. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. *Lancet.* 1991;338(8776):1175–6.

Yoshiko Azuma, Nakaya, A., Shinya, F., Atsushi, S., *et al.* Neutrophil-to-lymphocyte ratio (NLR) fails to predict outcome of diffuse large B cell lymphoma. 2019. <https://doi.org/10.1016/j.lrr.2019.100173>.

Zhao, P., Zang, L., Zhang, X., Chen, Y., Yue, Z., Yng, H., *et al.* Novel Prognostic Scoring System for Diffuse Large B cell Lymphoma. *Oncol Lett.* 2018; 15(4): 5325-5332

Zhou, M., Wang, J., Ouyang, J., Xu, J.Y., Chen, B., Zhang, Q.G., Zhou, R.F., *et al.* MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy. *Tumour Biol* 2014; 35: 6757-62.

Zhou, Z., Sehn, L.H., Rademaker, A.W., Gordon, L.I., Lacasce, A.S., Crosby-Thompson, A., Vanderplas, A., Zelenetz, A.D., *et al.* An enhanced International Prognostic Index (NCCN-IPi) for patients with diffuse large B-cell lymphoma treated in the rituximab era. *Blood* 2014; 123: 837-42.